Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Pharmaceuticals
- Delivery
- Disease
- Therapeutic
- Cancer
- cardiac
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 29425
License Grant
Licensor announced an amended agreement with respect to Paxil CR (paroxetine).
License Property
Paxil CR, a controlled release version of the much prescribed drug prescribed for central nervous system disorders. Paxil CR is a modified release version of Paxil/Seroxat (paroxetine) using a combination of the Positioned Release and Zero Order Geomatrix systems.
Paxil CRâ„¢ is a modified release version of Paxil/Seroxat (paroxetine HCL) which uses a combination of the Positioned Release and Zero Order Geomatrixâ„¢ systems. Paxil is an FDA-approved drug that is currently marketed primarily in the United States and Europe and is an immediate release formulation prescribed for central nervous system disorders.
Field of Use
Geomatrixâ„¢ is a range of technologies by which drugs taken orally in tablet form are formulated so as to control the amount, timing and location of the release of the drug in the body.
IPSCIO Record ID: 27477
License Grant
Licensor granted right to technology used in development in a new version of Paxil.
License Property
Paxil CR is a controlled release version of the much prescribed drug prescribed for central nervous system disorders.
Paxil CR is a modified release version of Paxil/Seroxat (paroxetine) using a combination of the Positioned Release and Zero Order Geomatrix systems. Paxil is an FDA-approved (February 1999) drug that is currently marketed primarily in the United States and Europe. In early 2001 an approvable letter from the FDA was received for a second CR indication, panic disorder. A third CR indication, pre-menstrual dysphoric disorder, a severe form of pre-menstrual syndrome is being developed. In April, 2002, the product was launched in the U.S. Note that in May 2005, they renegotiated this license and the upper range of the royalty payment was increased.
Field of Use
The rights granted apply to the healthcare industry.
IPSCIO Record ID: 29294
License Grant
The Company granted the development partners exclusive licenses to use the Geomatrix technology in products throughout the world.
License Property
A significant part of the Company's business is developing applications of its Geomatrix(TM) technologies. Geomatrix is a range of technologies by which drugs taken orally in tablet form are formulated so as to control the amount, timing and location of the release of the drug in the body. The Company focuses its research and development efforts on the reformulation of existing drugs using its technologies rather than the discovery of new chemical compounds.
Field of Use
Xatral 10mg OD is a once per day Zero Order Geomatrix formulation of Alfuzosin used for the treatment of the functional symptoms of benign prostatic hyperplasia (BPH), a common disorder in men over the age of 50.
IPSCIO Record ID: 26466
License Grant
Under the terms of collaborative agreement in 1988, the Licensee bores all of the costs of research and development according to a budget agreed by the Company and Licensee. In return, the Company granted Licensee an exclusive license to market Dilacor XR throughout the world.
License Property
Dilacor XR is a once per day Zero Order Geomatrix formulation of diltiazem hydrochloride, a calcium channel blocking agent indicated for hypertension and for the management of chronic stable angina. Geomatrix technologies can improve the efficacy of orally administered drugs and enhance compliance by patients with prescribed medical treatments by permitting the drug to be taken less frequently, by reducing side effects and by causing the drug to be released at more specific locations within the body. The Geomatrix technologies use hydrophillicmethylcellulose, or HPMC, matrices which govern the release profile of a drug depending on the viscosity of HPMC used and the rate of surface area exposure. The 'release profile' refers to the rates at which a drug tablet releases the active drug component over the period of time after the drug is taken.
Field of Use
Dilacor XR (diltiazem hydrochloride) is a calcium channel blocker used to treat hypertension (high blood pressure), angina (chest pain), and certain heart rhythm disorders.
IPSCIO Record ID: 27061
License Grant
The Company has previously agreed to pay royalties to CONSULTANT, a member of the Company's Board of Directors, in recognition of the patents developed by CONSULTANT for TIMERx.
License Property
The Company has developed the TIMERx delivery system, a novel drug delivery technology, to address the limitations of currently available oral controlled release delivery systems. The Company believes that the TIMERx system is a major advancement in oral drug delivery that represents the first easily-manufactured oral controlled release drug delivery system that is applicable to a wide variety of drug classes, including soluble drugs, insoluble drugs and drugs with a narrow therapeutic index. The Company is utilizing the TIMERx system to formulate generic versions of branded controlled release drugs, controlled release formulations of currently-marketed.
The TIMERx drug delivery system is a hydrophilic matrix combining primarily a heterodispersed mixture, usually polysaccharides xanthan and locust bean gums, in the presence of dextrose. The physical interaction between these components works to form a strong, binding gel in the presence of water. Drug release is controlled by the rate of water penetration from the gastrointestinal tract into the TIMERx gum matrix, which expands to form a gel and subsequently releases the active drug substance. The TIMERx system can precisely control the release of the active drug substance in a tablet by varying the proportion of the gums, together with the third component, the tablet coating and the tablet manufacturing process. Drugs using TIMERx technology are formulated by combining the active drug substance, the TIMERx drug delivery system and additional excipients and compressing such materials into a tablet.
1) Directly compressible sustained release excipient.
2) Sustained release excipient and tablet formulation.
3) Compressible sustained release solid dosage forms.
4) EPO Application No. 89309518.2; filed September 19, 1989.
5) Australian Patent Application No. 43057/89
6) Japanese Patent Application No. 1-510135
7) Irish Patent Application No. 2968/89
8) Canadian Patent Application No. 611,700
9) Verapamil Tablet Application, Serial No. 736,031 & EPO PCT Applications.
10) 2 U.S. Applications on Bi-modal release.
IPSCIO Record ID: 336386
License Grant
Swiss Licensor hereby grants to English Licensee an exclusive license, with the right to grant sublicenses under the patents, SPCs and Licensor-Know-How to make, have made, use and sell product in the territory, subject to the terms and conditions of this agreement. The rights to make, have made, use and sell shall include all activities concerning the subject matter of patents, SPCs and Licensor-Know-How with respect to the making, use and sale of product only, which activities would, but for the license herein granted, infringe Patents, SPCs and/or Licensor-Know-How. In addition, Licensor hereby grants to Licensee an exclusive license, with the right to grant sublicenses subject to this agreement, to make, have made, use and sell any invention or know-how related to Product which arose under the Letter, whether patented and/or patentable or not, for any purpose directly related to any selective serotonin reuptake inhibitor, provided that Licensor shall be allowed to use any such invention or know-how and the patents covering same, if any, for any other purpose not directly related to any selective serotonin reuptake inhibitor.
License Property
Paroxetine shall mean the chemical compound known as paroxetine, the more specific chemical name of which is [(-)-trans-4-(4- fluorophenyl)-3-[3,4-methylene-dioxyphenoxy) methyl] piperidine] and all pharmaceutically active derivatives thereof such as, but not limited to esters, salts (such as, but not limited to, the hydrochloride salt), hydrates, solvates, polymorphs, prodrugs and isomers thereof.
Geomatrix® Technology shall mean Licensors proprietary oral, modified release (i.e., controlled-release, sustained-release, or delayed release) drug delivery and related technology which utilizes a hydrophilic drug-containing matrix tablet which controls the release of the drug through the use of one or more barrier layers, together with all improvements thereon or thereto.
Product shall mean shall mean an oral delivery system for Paroxetine based on or using the Geomatrix® Technology.
Patents shall mean
4,839,177 – System for the controlled-rate release of active substances
5,422,123 – Tablets with controlled-rate release of active substances
5,476,654 – Process for preparing pharmaceutical compositions having an increased active substance dissolution rate, and the compositions obtained
SPC shall mean a right based upon a patent to exclude others from making, using or selling product, such as a Supplementary Protection Certificate.
Field of Use
Licensee will utilize such technology to develop drugs taken orally in tablet form formulated so as to control the amount, timing and location of the release of the drug in the body for pharmaceutical use in human prescriptions.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
